In Rx Pricing Debate, House Dems Key On Stock Buybacks To Counter Worries About R&D Spending Cuts
Executive Summary
Of the 14 leading biopharma companies, only AstraZeneca and Roche spent more on R&D than on buybacks and dividends over the past five years, the report from the US House Committee on Oversight and Reform shows.